The National Agency for Medicines and Medical Devices (NAMMD) hereby
renews warnings to patients and the general public concerning purchase of
medicinal products over the Internet because of the serious risk of counterfeit
products of uncertain origin, composition and safety. The dose could be too high
or too low, or the product may be contaminated.

All persons with a medical condition and requiring treatment are advised to see
a healthcare professional and purchase medicinal products from authorised
sources only.

The NAMMD adheres to the warning by the UK Medicine and Healthcare
products Regulatory Agency – MHRA in its press release of 02/03/2015 on
GcMAF (Macrophage Activating Factor Globulin component) product:

https://www.gov.uk/government/news/regulator-warns-against-gcmaf-made-in-
unlicensed-facility-in-cambridgeshire

This concerns a blood product, claiming to treat a range of conditions including
cancer, HIV and autism. People who have bought this product are advised to
speak to their doctor.

The MHRA press release refers to findings of an unannounced inspection at a
manufacturing site in Milton, Cambridgeshire, concluding on non-compliance
with Good Manufacturing Practice (GMP) rules: the originating material (blood
plasma) was not suitable for human use, there were concerns over the sterility of
the product being manufactured and the equipment being used, as well as
concerns that the product may be contaminated.

The GcMAF product labelled "First Immune" has not been granted a marketing
authorisation and has not been tested in order to confirm its quality, safety or
efficacy.

The MHRA warning also indicates the websites providing for purchase of the
GcMAF product:

www.GcMAF.eu
www.immunobiotech.eu
www.immunocentre.eu
www.petgcmaf.com
www.firstimmune.fr
www.firstimmune.de
www.firstimmune.it
www.gcmaf.gr
www.gcmaf.se
www.gcmaf.es
The NAMMD hereby reiterates the primary objective of its work, i.e. protection and promotion of public health.